Direct-To-Consumer (DTC) Genetic Testing Market By Sales Channel (Online Sales, OTC Sales, Doctor’s Office), By Business Model (Genome Data Bank Material Model, Individual Health Planning Model, Comprehensive Genome Tests Model, Medical Precision Tests Model, Restricted Trait Tests Model) - Growth, Future Prospects And Competitive Analysis, 2018 – 2026

DTC genetic testing market poised to grow with a double-digit CAGR during the forecast period

Direct-to-consumer (DTC) genetic testing market is expected to reach US$ 611.24 Mn by 2026 with a 19.4% CAGR during the forecast period from 2018 to 2026, mostly through the online sales channel. OTC/Pharmacy Stores and Doctors’ offices are other sales channels dispensing these testing kits. Globally more than 200 companies are offering DTC genetic testing services, with prominent ones headquartered in North America having no clear majority of the market share held by any player. Products such as CentoDx Plus by Centogene AG, Ancestry kit by 23andMe, family finder test, Y-DNA, and mtDNA test by GenebyGene, Ltd. are a few of the products ordered through different distribution channels. Consumers buy these services and kits to obtain information about family lineage, disease risks, and personal traits.

Along with genetic testing kits, manufacturers and third parties provide additional services for interpreting the raw data. DTC, coupled with accessibility through online sales channels, procuring these services/kits has become hassle-free, with test results delivered to consumers’ doorstep. Online sales as a prime distribution channel are expected to grow with the highest CAGR during the forecast period. North America led the DTC genetic testing market in 2017, while the Asia Pacific is poised to emerge as the fastest-growing region between 2018 and 2026. The availability of a wide range of DTC genetic test kits through portals of manufacturers and third-party websites for consumers to choose from contributes to the overall remunerative growth of the DTC genetic testing market. 

Online sales channel propelling the growth of the DTC genetic testing market

Online sales are the largest distribution channel by value and are expected to retain prominence with the highest CAGR throughout the forecast period. With the ease of ordering these services/kits online just by a click through smartphones, DTC genetic testing market is experiencing tremendous traction when compared to other less preferred channels such as OTC and Doctors’ Office. In addition to manufacturers’ online portals alongside e-commerce portals such as Amazon, eBay, etc., and little or no critical guidance from physicians, online sales of DTC genetic testing kits and services are expected to flourish with a double-digit CAGR during the forecast period. Assuming the current regulatory pressure to remain constant or change with minimal impact, the Credence research team foresees online sales becoming the sole distribution channel in years to come. At the same time, the online sales channel overcomes the geographic barrier, thereby promising vast outreach worldwide.

Medical precision test segment to record highest double-digit CAGR during the forecast period

Almost all the business models, such as genome data bank material, individual health planning, comprehensive genome test, medical precision test, and restricted trait test, promise lucrative returns tailing the medical precision test model poised to exhibit the fastest CAGR during the forecast period. In 2017, the genome data bank material model held the largest market share by value and was expected to maintain its pole position throughout the forecast period.

23andMe is amongst the prominent players offering genomic test kits under this model with either health-related genome sequencing or health and ancestry-related genome sequencing. The currently available services include testing for ancestral data related to family lineage, identification of health risks and risk of acquiring hereditary diseases, information about genomic patterns, and knowledge of personal traits. With the increased prevalence of genetic diseases and specific cancers, the curiosity to know individual risks is expected to drive the sales of the medical precision test model.

The rapid proliferation of genetic testing in the Asia Pacific set the stage for the fastest growth during the forecast period.

North America, with key players headquartered there, stands distinctly with most of the market share, followed by Europe, with Asia pacific left not far behind. The Middle East & Africa and LatAm are the fastest growing markets tailing Asia Pacific. Growing awareness and rapid development of healthcare infrastructure in developing regions are the prime market drivers. Due to the multitude of hospital admissions and the growing need for containment of rising morbidity, stringent guidelines for infection reduction and the consequent need for culminating the risk of readmission in hospitals have urged the emerging markets to grow rapidly CAGR during the forecast period.

Inquisitiveness to know lineage, increasing awareness about the risk of genetic diseases, and growing proactive tendency among the public about prevention and efficient management of chronic diseases is mainly attributed to the dominance of the North American market. The structure of regulatory guidelines about the use of genetic testing also plays a critical role in driving the market in developed regions.

US$ 491 million in funding, 23andMe is one of the promising players in the direct-to-consumer genetic testing market

23andMe was the first company to receive FDA approval to market genetic test kits direct to consumers. The company markets tests on genetic risk for ten conditions, covering Parkinson’s disease, late-onset Alzheimer’s disease, hereditary thrombophilia (harmful blood clusters), and celiac disease, among others. 23andMe discontinued its DTC genetic testing products in 2013 after being ordered by the US FDA due to the health consequences of inaccurate results. However, the company after that, presented validation data on its DTC testing kits and services for 36 diseases to the FDA and re-launched its products after consequent approval in 2015. Other notable players competing in DTC genetic testing market are Navigenics, deCODE genetics, Myriad Genetics, Centogene, etc.

Report Scope by Segments

DTC genetic testing market report presents the current market dynamics along with a quantitative analysis of the global market. In addition, the report elucidates the detailed outline of the global DTC genetic testing market by categorizing the market in terms of sales channel, business model, and geography. The objective of publishing this extensive research report is to aid healthcare professionals and market stakeholders make better decisions and strategic initiatives in the DTC genetic testing market.

Sales Channel Segment (2016–2026; US$ Mn)

  • Online Sales
  • OTC Sales
  • Doctor’s Office

Business Model Segment (2016–2026; US$ Mn)

  • Genome Data Bank Material Model
  • Individual Health Planning Model
  • Comprehensive Genome Tests Model
  • Medical Precision Tests Model
  • Restricted Trait Tests Model

Geography Segment (2016–2026; US$ Mn)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

This research report further describes the major qualitative market assessment factors, including key market trends, market drivers, and restraints, to aid in a better understanding of the global DTC genetic testing market. Each market assessment factor, including market drivers, challenges, and opportunities, is extensively explained, considering the current market scenario.

This report graphically maps the market players based on their market initiatives and strategies, product offerings, and business strength. Furthermore, the report provides an attractive investment proposition based on extensive geographical research. Key players profiled in the report include deCODE genetics, Inc., Color Genomics, Inc., Gene By Gene, Ltd., Ancestry.com, Inc., Myriad Genetics, Inc., Genleven Oy, 23andMe, Inc., and CENTOGENE AG.

Frequently Asked Questions:

The market for Direct-To-Consumer (DTC) Genetic Testing is expected to reach US$ 611.24 Mn by 2026.

The Direct-To-Consumer (DTC) Genetic Testing market is expected to see significant CAGR growth over the coming years, at 19.4%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

deCODE genetics, Inc., Business Description, Financial Information (Subject to data availability), Application Portfolio, Key Developments, Color Genomics, Inc., Gene By Gene, Ltd., Ancestry.com, Inc., Myriad Genetics, Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Feb 2018
Category:  Medical Devices
Report ID:   57820
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support